'It's Totally Irresponsible': Canadian Ethicist Slams Rogue Russian's Plan to Edit Human Embryos
By Gemma Buck,
National Post
| 07. 08. 2019
Canadian bioethicists and genetics experts are speaking out against Denis Rebrikov, the Russian molecular biologist who plans — in defiance of international scientific norms — to alter human embryos using CRISPR gene-editing technology to allow prospective parents with genetic deafness to conceive a child who can hear.
“We are putting ourselves on the path to changing the human evolutionary story. This is not up to one scientist. It’s not up to a group of scientists or a group of political elites. It’s up to all of us,” said Françoise Baylis, a professor of philosophy and bioethics at Dalhousie University who serves on a World Health Organization committee that is developing global standards and oversight for editing of the human genome.
The ethical implications of this kind of rogue science are wide-ranging and nuanced, Baylis explained. But the obvious ones are dire: Making genetic changes to eggs, sperm, or early embryos, collectively called the human germline, affects not only the eventual person these cells may become, but also their offspring.Though there is a “spectrum” of views among scientists and ethicists about...
Related Articles
By Hannah Devlin, The Guardian | 05.14.2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success...
By Victoria Bisset and Adela Suliman, The Washington Post | 05.09.2024
Photo by CDC from Unsplash
A baby girl born with profound genetic deafness can now hear unaided after receiving a “groundbreaking” gene therapy trial, Britain’s National Health Service said Thursday.
Opal Sandy, an 18-month-old from Oxfordshire, England, is the first...
By Carrie Arnold, Nature Biotechnology | 04.17.2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to...
By Rob Stein, NPR | 04.24.2024
Lisa Pisano was lying in a hospital bed at NYU Langone Health, hooked up to beeping monitors and an array of tubes. Her surgical wounds were still healing, and she looked tired. But the 54-year-old New Jersey woman said she...